Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

Core Insights - Oragenics, Inc. has regained full compliance with NYSE American's continued listing standards, allowing the company to focus on advancing its lead clinical program [1] Group 1 - The company is a clinical-stage biotechnology firm developing brain-targeted therapeutics through proprietary intranasal delivery technology [1] - NYSE American notified Oragenics of compliance regaining effective October 20, 2025 [1]